{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:15:46Z","timestamp":1793499346929,"version":"4.5.0"},"reference-count":124,"publisher":"Galenos Yayinevi","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"DOI":"10.4274\/tjo.galenos.2024.77783","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T06:07:42Z","timestamp":1735798062000},"page":"354-357","source":"Crossref","is-referenced-by-count":3,"title":["An Unusual Case of Low Vision and Anisocoria Considered a Neurological Finding in the Emergency Department: Ocular Siderosis"],"prefix":"10.4274","volume":"54","author":[{"given":"Osman","family":"\u00d6zen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menek\u015fe","family":"\u0130nal \u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","unstructured":"1) Kumar, S.K., Rajkumar, V., Kyle, R.A., van Duin, M., Sonneveld, P., Mateos, M.V., Gay, F. and Anderson, K.C. (2017) Multiple myeloma. Nat Rev Dis Primers 3, 17046.","journal-title":"Nat Rev Dis Primers"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","unstructured":"2) Mateos, M.V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N., Ocio, E.M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J.M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H. and Moreau, P. (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36, 1371-1376.","journal-title":"Leukemia"},{"key":"ref2","unstructured":"3) Gulla, A. and Anderson, K.C. (2020) Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/j.1349-7006.2012.02384.x","article-title":"Model of translational cancer research in multiple myeloma","volume":"103","author":"Yasui","year":"2012","unstructured":"4) Yasui, H., Ishida, T., Maruyama, R., Nojima, M., Ikeda, H., Suzuki, H., Hayashi, T., Shinomura, Y. and Imai, K. (2012) Model of translational cancer research in multiple myeloma. Cancer Sci 103, 1907-1912.","journal-title":"Cancer Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","unstructured":"5) Lim, W.A. and June, C.H. (2017) The Principles of Engineering Immune Cells to Treat Cancer. Cell 168, 724-740.","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","unstructured":"6) June, C.H. and Sadelain, M. (2018) Chimeric Antigen Receptor Therapy. N Engl J Med 379, 64-73.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","unstructured":"7) Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K.L., Martin, P.L., Nemecek, E.R., Yanik, G.A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C.H., Levine, B.L., Wood, P., Taran, T., Leung, M., Mueller, K.T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M.A. and Grupp, S.A. (2018) Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 378, 439-448.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","unstructured":"8) Schuster, S.J., Tam, C.S., Borchmann, P., Worel, N., McGuirk, J.P., Holte, H., Waller, E.K., Jaglowski, S., Bishop, M.R., Damon, L.E., Foley, S.R., Westin, J.R., Fleury, I., Ho, P.J., Mielke, S., Teshima, T., Janakiram, M., Hsu, J.M., Izutsu, K., Kersten, M.J., Ghosh, M., Wagner-Johnston, N., Kato, K., Corradini, P., Martinez-Prieto, M., Han, X., Tiwari, R., Salles, G. and Maziarz, R.T. (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22, 1403-1415.","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","unstructured":"9) Jacobson, C.A., Chavez, J.C., Sehgal, A.R., William, B.M., Munoz, J., Salles, G., Munshi, P.N., Casulo, C., Maloney, D.G., de Vos, S., Reshef, R., Leslie, L.A., Yakoub-Agha, I., Oluwole, O.O., Fung, H.C.H., Rosenblatt, J., Rossi, J.M., Goyal, L., Plaks, V., Yang, Y., Vezan, R., Avanzi, M.P. and Neelapu, S.S. (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23, 91-103.","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","unstructured":"10) Munshi, N.C., Anderson, L.D., Jr., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J.N., Kaiser, S., Patel, P., Huang, L., Campbell, T.B., Hege, K. and San-Miguel, J. (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384, 705-716.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","unstructured":"11) Sanchez, E., Li, M., Kitto, A., Li, J., Wang, C.S., Kirk, D.T., Yellin, O., Nichols, C.M., Dreyer, M.P., Ahles, C.P., Robinson, A., Madden, E., Waterman, G.N., Swift, R.A., Bonavida, B., Boccia, R., Vescio, R.A., Crowley, J., Chen, H. and Berenson, J.R. (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 158, 727-738.","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","unstructured":"12) Novak, A.J., Darce, J.R., Arendt, B.K., Harder, B., Henderson, K., Kindsvogel, W., Gross, J.A., Greipp, P.R. and Jelinek, D.F. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689-694.","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","unstructured":"13) Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M.V., Turka, A., Lam, L.P., Morgan, R.A., Friedman, K., Massaro, M., Wang, J., Russotti, G., Yang, Z., Campbell, T., Hege, K., Petrocca, F., Quigley, M.T., Munshi, N. and Kochenderfer, J.N. (2019) Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 380, 1726-1737.","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","unstructured":"14) Martin, T., Usmani, S.Z., Berdeja, J.G., Agha, M., Cohen, A.D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., Munshi, N.C., O'Donnell, E., Stewart, A.K., Schecter, J.M., Goldberg, J.D., Jackson, C.C., Yeh, T.M., Banerjee, A., Allred, A., Zudaire, E., Deraedt, W., Olyslager, Y., Zhou, C., Pacaud, L., Madduri, D., Jakubowiak, A., Lin, Y. and Jagannath, S. (2023) Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 41, 1265-1274.","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","unstructured":"15) Berdeja, J.G., Madduri, D., Usmani, S.Z., Jakubowiak, A., Agha, M., Cohen, A.D., Stewart, A.K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N.C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T.M., Allred, A.J., Olyslager, Y., Banerjee, A., Jackson, C.C., Goldberg, J.D., Schecter, J.M., Deraedt, W., Zhuang, S.H., Infante, J., Geng, D., Wu, X., Carrasco-Alfonso, M.J., Akram, M., Hossain, F., Rizvi, S., Fan, F., Lin, Y., Martin, T. and Jagannath, S. (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314-324.","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata","year":"2023","unstructured":"16) Minakata, D., Ishida, T., Ando, K., Suzuki, R., Tanaka, J., Hagiwara, S., Ananthakrishnan, R., Kuwayama, S., Nishio, M., Kanda, Y. and Suzuki, K. (2023) Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol 117, 729-737.","journal-title":"Int J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","unstructured":"17) Xu, J., Wang, B.Y., Yu, S.H., Chen, S.J., Yang, S.S., Liu, R., Chen, L.J., Hou, J., Chen, Z., Zhao, W.H., He, A.L., Mi, J.Q. and Chen, S.J. (2024) Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol 17, 23.","journal-title":"J Hematol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","unstructured":"18) Anderson, L.D., Jr., Dhakal, B., Jain, T., Oluwole, O.O., Shah, G.L., Sidana, S., Perales, M.A. and Pasquini, M.C. (2024) Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 30, 17-37.","journal-title":"Transplant Cell Ther"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19) Boulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaitre, F., Grandjean, C.L., Garcia, Z. and Bousso, P. (2021) A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol 6.","DOI":"10.1126\/sciimmunol.abd4344"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","unstructured":"20) Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843-851.","journal-title":"Mol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","unstructured":"21) Parkhurst, M.R., Yang, J.C., Langan, R.C., Dudley, M.E., Nathan, D.A., Feldman, S.A., Davis, J.L., Morgan, R.A., Merino, M.J., Sherry, R.M., Hughes, M.S., Kammula, U.S., Phan, G.Q., Lim, R.M., Wank, S.A., Restifo, N.P., Robbins, P.F., Laurencot, C.M. and Rosenberg, S.A. (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19, 620-626.","journal-title":"Mol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers","volume":"24","author":"Guo","year":"2018","unstructured":"22) Guo, Y., Feng, K., Liu, Y., Wu, Z., Dai, H., Yang, Q., Wang, Y., Jia, H. and Han, W. (2018) Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clin Cancer Res 24, 1277-1286.","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","unstructured":"23) Melenhorst, J.J., Chen, G.M., Wang, M., Porter, D.L., Chen, C., Collins, M.A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., Lundh, S., Pruteanu-Malinici, I., Nobles, C.L., Maji, S., Frey, N.V., Gill, S.I., Loren, A.W., Tian, L., Kulikovskaya, I., Gupta, M., Ambrose, D.E., Davis, M.M., Fraietta, J.A., Brogdon, J.L., Young, R.M., Chew, A., Levine, B.L., Siegel, D.L., Alanio, C., Wherry, E.J., Bushman, F.D., Lacey, S.F., Tan, K. and June, C.H. (2022) Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602, 503-509.","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"777073","DOI":"10.3389\/fimmu.2021.777073","article-title":"Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies","volume":"12","author":"Polania","year":"2021","unstructured":"24) Waibl Polania, J., Lerner, E.C., Wilkinson, D.S., Hoyt-Miggelbrink, A. and Fecci, P.E. (2021) Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Front Immunol 12, 777073.","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-022-31818-y","article-title":"High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance","volume":"13","author":"Cortes-Lopez","year":"2022","unstructured":"25) Cortes-Lopez, M., Schulz, L., Enculescu, M., Paret, C., Spiekermann, B., Quesnel-Vallieres, M., Torres-Diz, M., Unic, S., Busch, A., Orekhova, A., Kuban, M., Mesitov, M., Mulorz, M.M., Shraim, R., Kielisch, F., Faber, J., Barash, Y., Thomas-Tikhonenko, A., Zarnack, K., Legewie, S. and Konig, J. (2022) High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance. Nat Commun 13, 5570.","journal-title":"Nat Commun"},{"key":"ref25","unstructured":"26) Ishida, T., Thompson, E.G., Piasecki, P., Rodriguez-Otero, P., Mateos, M.-V., Arnulf, B., Desai, K., Wu, F., Courtney, C., Cook, M., Martin, N. and Iida, S. (2024) Association of patient factors and pharmacodynamic biomarkers with PFS after ide-cel in KarMMa-3, The 86th Annual Meeting of the Japanese Society of Hematology. Kyoto, Japan."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jtct.2024.03.003","article-title":"Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed\/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study","author":"Caillot","year":"2024","unstructured":"27) Caillot, L., Sleiman, E., Lafon, I., Chretien, M.L., Gueneau, P., Payssot, A., Pedri, R., Lakomy, D., Bailly, F., Guy, J., Quenot, J.P., Avet-Loiseau, H. and Caillot, D. (2024) Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed\/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Transplant Cell Ther 30, 630 e631-630 e638.","journal-title":"Transplant Cell Ther 30 630 e631-630 e"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"101306","DOI":"10.1016\/j.beha.2021.101306","article-title":"Clinical experience of CAR T cells for multiple myeloma","volume":"34","author":"Simmons","year":"2021","unstructured":"28) Simmons, G.L., Satta, T. and Castaneda Puglianini, O. (2021) Clinical experience of CAR T cells for multiple myeloma. Best Pract Res Clin Haematol 34, 101306.","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","unstructured":"29) Cohen, A.D., Garfall, A.L., Stadtmauer, E.A., Melenhorst, J.J., Lacey, S.F., Lancaster, E., Vogl, D.T., Weiss, B.M., Dengel, K., Nelson, A., Plesa, G., Chen, F., Davis, M.M., Hwang, W.T., Young, R.M., Brogdon, J.L., Isaacs, R., Pruteanu-Malinici, I., Siegel, D.L., Levine, B.L., June, C.H. and Milone, M.C. (2019) B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129, 2210-2221.","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"101459","DOI":"10.1016\/j.tranon.2022.101459","article-title":"Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies","volume":"22","author":"Atilla","year":"2022","unstructured":"30) Atilla, P.A. and Atilla, E. (2022) Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. Transl Oncol 22, 101459.","journal-title":"Transl Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","unstructured":"31) Liu, Y., Zhou, X. and Wang, X. (2021) Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol 14, 125.","journal-title":"J Hematol Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","unstructured":"32) Loeuillard, E., Yang, J., Buckarma, E., Wang, J., Liu, Y., Conboy, C., Pavelko, K.D., Li, Y., O'Brien, D., Wang, C., Graham, R.P., Smoot, R.L., Dong, H. and Ilyas, S. (2020) Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 130, 5380-5396.","journal-title":"J Clin Invest"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","unstructured":"33) Gabrilovich, D.I. (2017) Myeloid-Derived Suppressor Cells. Cancer Immunol Res 5, 3-8.","journal-title":"Cancer Immunol Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","unstructured":"34) Togashi, Y., Shitara, K. and Nishikawa, H. (2019) Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 16, 356-371.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance","volume":"37","author":"Munn","year":"2016","unstructured":"35) Munn, D.H. and Mellor, A.L. (2016) IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol 37, 193-207.","journal-title":"Trends Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1073\/pnas.2119463119","article-title":"Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack","author":"Wang","year":"2022","unstructured":"36) Wang, Z., Moresco, P., Yan, R., Li, J., Gao, Y., Biasci, D., Yao, M., Pearson, J., Hechtman, J.F., Janowitz, T., Zaidi, R.M., Weiss, M.J. and Fearon, D.T. (2022) Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack. Proc Natl Acad Sci U S A 119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","unstructured":"37) Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., Savino, B., Colombo, P., Jonjic, N., Pecanic, S., Lazzarato, L., Fruttero, R., Gasco, A., Bronte, V. and Viola, A. (2011) Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208, 1949-1962.","journal-title":"J Exp Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1158\/2326-6066.CIR-20-0837","article-title":"CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNgamma and ICAM-1","volume":"9","author":"Kantari-Mimoun","year":"2021","unstructured":"38) Kantari-Mimoun, C., Barrin, S., Vimeux, L., Haghiri, S., Gervais, C., Joaquina, S., Mittelstaet, J., Mockel-Tenbrinck, N., Kinkhabwala, A., Damotte, D., Lupo, A., Sibony, M., Alifano, M., Dondi, E., Bercovici, N., Trautmann, A., Kaiser, A.D. and Donnadieu, E. (2021) CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNgamma and ICAM-1. Cancer Immunol Res 9, 1425-1438.","journal-title":"Cancer Immunol Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","unstructured":"39) Larson, R.C., Kann, M.C., Bailey, S.R., Haradhvala, N.J., Llopis, P.M., Bouffard, A.A., Scarfo, I., Leick, M.B., Grauwet, K., Berger, T.R., Stewart, K., Anekal, P.V., Jan, M., Joung, J., Schmidts, A., Ouspenskaia, T., Law, T., Regev, A., Getz, G. and Maus, M.V. (2022) CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature 604, 563-570.","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1182\/bloodadvances.2022007891","article-title":"CD58 loss in tumor cells confers functional impairment of CAR T cells","volume":"6","author":"Yan","year":"2022","unstructured":"40) Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., Tong, C., Zhu, Q., Lu, Y., Yu, Y., Wu, Z. and Han, W. (2022) CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv 6, 5844-5856.","journal-title":"Blood Adv"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","unstructured":"41) Laurent, S.A., Hoffmann, F.S., Kuhn, P.H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S.M., Schuh, E., Krumbholz, M., Rubsamen, H., Wanngren, J., Khademi, M., Olsson, T., Alexander, T., Hiepe, F., Pfister, H.W., Weber, F., Jenne, D., Wekerle, H., Hohlfeld, R., Lichtenthaler, S.F. and Meinl, E. (2015) gamma-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6, 7333.","journal-title":"Nat Commun"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","unstructured":"42) Pont, M.J., Hill, T., Cole, G.O., Abbott, J.J., Kelliher, J., Salter, A.I., Hudecek, M., Comstock, M.L., Rajan, A., Patel, B.K.R., Voutsinas, J.M., Wu, Q., Liu, L., Cowan, A.J., Wood, B.L., Green, D.J. and Riddell, S.R. (2019) gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134, 1585-1597.","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43) Bachl, S., Talbot, A., Ching, C., Kale, N., Li, Z., Diolaiti, M., Chen, A.P., Muldoon, J., Liu, C., Martin, T., Eyquem, J. and Carnevale, J. (2023) Ablation of cullin-5 in primary human T cells improves tumor killing and persistence in BCMA-targeting CAR-T cells in a multiple myeloma model, The 65th American Society of Hematology annual meeting, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-182565"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","unstructured":"44) Yuti, P., Sawasdee, N., Natungnuy, K., Rujirachaivej, P., Luangwattananun, P., Sujjitjoon, J. and Yenchitsomanus, P.T. (2023) Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. Biomed Pharmacother 168, 115691.","journal-title":"Biomed Pharmacother"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45) Jakubikova, J., Cholujova, D., Beke, G., Hideshima, T., Klucar, L., Leiba, M., Jamroziak, K., Richardson, P.G., Kastritis, E., Dorfman, D.M. and Anderson, K.C. (2023) Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. JCI Insight 8.","DOI":"10.1172\/jci.insight.159924"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1182\/blood.2022018658","article-title":"Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy","volume":"143","author":"Tang","year":"2024","unstructured":"46) Tang, Y., Liu, W., Kadu, S., Johnson, O., Hasanali, Z.S., Kelly, A., Shestov, A., Pajarillo, R., Greenblatt, E., Holmes, M., Wang, L.P., Shih, N., O'Connor, R.S., Ruella, M., Garfall, A.L., Allman, D., Vogl, D.T., Cohen, A., June, C.H. and Sheppard, N.C. (2024) Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy. Blood 143, 139-151.","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","unstructured":"47) Zhou, J.E., Sun, L., Jia, Y., Wang, Z., Luo, T., Tan, J., Fang, X., Zhu, H., Wang, J., Yu, L. and Yan, Z. (2022) Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release 350, 298-307.","journal-title":"J Control Release"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","author":"Smith","year":"2019","unstructured":"48) Smith, E.L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T.J., Ng, K.Y., Ghoddusi, M., Purdon, T.J., Wang, X., Do, T., Pham, M.T., Brown, J.M., De Larrea, C.F., Olson, E., Peguero, E., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S.C., Almo, S.C., Wendel, H.G., Riviere, I., Liu, C., Sather, B. and Brentjens, R.J. (2019) GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 11.","journal-title":"Sci Transl Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","unstructured":"49) Mailankody, S., Devlin, S.M., Landa, J., Nath, K., Diamonte, C., Carstens, E.J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., Wang, X., Sikder, D., Senechal, B., Bermudez, V.P., Purdon, T.J., Hosszu, K., McAvoy, D.P., Farzana, T., Mead, E., Wilcox, J.A., Santomasso, B.D., Shah, G.L., Shah, U.A., Korde, N., Lesokhin, A., Tan, C.R., Hultcrantz, M., Hassoun, H., Roshal, M., Sen, F., Dogan, A., Landgren, O., Giralt, S.A., Park, J.H., Usmani, S.Z., Riviere, I., Brentjens, R.J. and Smith, E.L. (2022) GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med 387, 1196-1206.","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.1373518","article-title":"CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes","volume":"256","author":"Carter","year":"1992","unstructured":"50) Carter, R.H. and Fearon, D.T. (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-107.","journal-title":"Science"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","unstructured":"51) Anderson, K.C., Bates, M.P., Slaughenhoupt, B.L., Pinkus, G.S., Schlossman, S.F. and Nadler, L.M. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63, 1424-1433.","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","unstructured":"52) Pasquini, M.C., Hu, Z.H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M.A., Phillips, C.L., Keating, A., Frigault, M.J., Salzberg, D., Jaglowski, S., Sasine, J.P., Rosenthal, J., Ghosh, M., Landsburg, D., Margossian, S., Martin, P.L., Kamdar, M.K., Hematti, P., Nikiforow, S., Turtle, C., Perales, M.A., Steinert, P., Horowitz, M.M., Moskop, A., Pacaud, L., Yi, L., Chawla, R., Bleickardt, E. and Grupp, S. (2020) Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4, 5414-5424.","journal-title":"Blood Adv"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","unstructured":"53) Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., Jager, U., Jaglowski, S., Andreadis, C., Westin, J.R., Fleury, I., Bachanova, V., Foley, S.R., Ho, P.J., Mielke, S., Magenau, J.M., Holte, H., Pantano, S., Pacaud, L.B., Awasthi, R., Chu, J., Anak, O., Salles, G., Maziarz, R.T. and Investigators, J. (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380, 45-56.","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","unstructured":"54) Neelapu, S.S., Locke, F.L., Bartlett, N.L., Lekakis, L.J., Miklos, D.B., Jacobson, C.A., Braunschweig, I., Oluwole, O.O., Siddiqi, T., Lin, Y., Timmerman, J.M., Stiff, P.J., Friedberg, J.W., Flinn, I.W., Goy, A., Hill, B.T., Smith, M.R., Deol, A., Farooq, U., McSweeney, P., Munoz, J., Avivi, I., Castro, J.E., Westin, J.R., Chavez, J.C., Ghobadi, A., Komanduri, K.V., Levy, R., Jacobsen, E.D., Witzig, T.E., Reagan, P., Bot, A., Rossi, J., Navale, L., Jiang, Y., Aycock, J., Elias, M., Chang, D., Wiezorek, J. and Go, W.Y. (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377, 2531-2544.","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","author":"Porter","year":"2015","unstructured":"55) Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., Gonzalez, V., Ambrose, D., Grupp, S.A., Chew, A., Zheng, Z., Milone, M.C., Levine, B.L., Melenhorst, J.J. and June, C.H. (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7, 303ra139.","journal-title":"Sci Transl Med 7 303ra"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","unstructured":"56) Wang, M., Munoz, J., Goy, A., Locke, F.L., Jacobson, C.A., Hill, B.T., Timmerman, J.M., Holmes, H., Jaglowski, S., Flinn, I.W., McSweeney, P.A., Miklos, D.B., Pagel, J.M., Kersten, M.J., Bouabdallah, K., Khanal, R., Topp, M.S., Houot, R., Beitinjaneh, A., Peng, W., Fang, X., Shen, R.R., Siddiqi, R., Kloos, I. and Reagan, P.M. (2023) Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol 41, 555-567.","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","article-title":"Differentiation stage of myeloma plasma cells: biological and clinical significance","volume":"31","author":"Paiva","year":"2017","unstructured":"57) Paiva, B., Puig, N., Cedena, M.T., de Jong, B.G., Ruiz, Y., Rapado, I., Martinez-Lopez, J., Cordon, L., Alignani, D., Delgado, J.A., van Zelm, M.C., Van Dongen, J.J., Pascual, M., Agirre, X., Prosper, F., Martin-Subero, J.I., Vidriales, M.B., Gutierrez, N.C., Hernandez, M.T., Oriol, A., Echeveste, M.A., Gonzalez, Y., Johnson, S.K., Epstein, J., Barlogie, B., Morgan, G.J., Orfao, A., Blade, J., Mateos, M.V., Lahuerta, J.J. and San-Miguel, J.F. (2017) Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia 31, 382-392.","journal-title":"Leukemia"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","unstructured":"58) Nerreter, T., Letschert, S., Gotz, R., Doose, S., Danhof, S., Einsele, H., Sauer, M. and Hudecek, M. (2019) Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun 10, 3137.","journal-title":"Nat Commun"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","unstructured":"59) Garfall, A.L., Maus, M.V., Hwang, W.T., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Zheng, Z., Vogl, D.T., Cohen, A.D., Weiss, B.M., Dengel, K., Kerr, N.D., Bagg, A., Levine, B.L., June, C.H. and Stadtmauer, E.A. (2015) Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med 373, 1040-1047.","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"60) Garfall, A.L., Stadtmauer, E.A., Hwang, W.T., Lacey, S.F., Melenhorst, J.J., Krevvata, M., Carroll, M.P., Matsui, W.H., Wang, Q., Dhodapkar, M.V., Dhodapkar, K., Das, R., Vogl, D.T., Weiss, B.M., Cohen, A.D., Mangan, P.A., Ayers, E.C., Nunez-Cruz, S., Kulikovskaya, I., Davis, M.M., Lamontagne, A., Dengel, K., Kerr, N.D., Young, R.M., Siegel, D.L., Levine, B.L., Milone, M.C., Maus, M.V. and June, C.H. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3.","DOI":"10.1172\/jci.insight.120505"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","article-title":"Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies","volume":"99","author":"Davila","year":"2014","unstructured":"61) Davila, M.L., Bouhassira, D.C., Park, J.H., Curran, K.J., Smith, E.L., Pegram, H.J. and Brentjens, R. (2014) Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 99, 361-371.","journal-title":"Int J Hematol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.matbio.2013.10.005","article-title":"Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse","volume":"35","author":"Ramani","year":"2014","unstructured":"62) Ramani, V.C. and Sanderson, R.D. (2014) Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol 35, 215-222.","journal-title":"Matrix Biol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","unstructured":"63) Hosen, N., Matsunaga, Y., Hasegawa, K., Matsuno, H., Nakamura, Y., Makita, M., Watanabe, K., Yoshida, M., Satoh, K., Morimoto, S., Fujiki, F., Nakajima, H., Nakata, J., Nishida, S., Tsuboi, A., Oka, Y., Manabe, M., Ichihara, H., Aoyama, Y., Mugitani, A., Nakao, T., Hino, M., Uchibori, R., Ozawa, K., Baba, Y., Terakura, S., Wada, N., Morii, E., Nishimura, J., Takeda, K., Oji, Y., Sugiyama, H., Takagi, J. and Kumanogoh, A. (2017) The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med 23, 1436-1443.","journal-title":"Nat Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/25785826.2020.1796063","article-title":"CAR T cell therapy","volume":"44","author":"Hosen","year":"2021","unstructured":"64) Hosen, N. (2021) CAR T cell therapy. Immunol Med 44, 69-73.","journal-title":"Immunol Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","unstructured":"65) Stewart, A.K., Krishnan, A.Y., Singhal, S., Boccia, R.V., Patel, M.R., Niesvizky, R., Chanan-Khan, A.A., Ailawadhi, S., Brumm, J., Mundt, K.E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A.G., Samineni, D., Leipold, D., Humke, E.W., McClellan, J.S. and Berdeja, J.G. (2019) Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J 9, 17.","journal-title":"Blood Cancer J"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","unstructured":"66) Yu, Z., Li, H., Lu, Q., Zhang, Z., Tong, A. and Niu, T. (2024) Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. Signal Transduct Target Ther 9, 16.","journal-title":"Signal Transduct Target Ther"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","unstructured":"67) Jiang, D., Huang, H., Qin, H., Tang, K., Shi, X., Zhu, T., Gao, Y., Zhang, Y., Tian, X., Fu, J., Qu, W., Cai, W., Xu, Y., Wu, D. and Chu, J. (2023) Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun 14, 3642.","journal-title":"Nat Commun"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","unstructured":"68) Radhakrishnan, S.V., Luetkens, T., Scherer, S.D., Davis, P., Vander Mause, E.R., Olson, M.L., Yousef, S., Panse, J., Abdiche, Y., Li, K.D., Miles, R.R., Matsui, W., Welm, A.L. and Atanackovic, D. (2020) CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun 11, 798.","journal-title":"Nat Commun"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"69) Vander Mause, E.R., Baker, J.M., Dietze, K.A., Radhakrishnan, S.V., Iraguha, T., Omili, D., Davis, P., Chidester, S.L., Modzelewska, K., Panse, J., Marvin, J.E., Olson, M.L., Steinbach, M., Ng, D.P., Lim, C.S., Atanackovic, D. and Luetkens, T. (2023) Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Sci Transl Med 15, eadd7900.","DOI":"10.1126\/scitranslmed.add7900"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11101611","article-title":"Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method","author":"Flieswasser","year":"2019","unstructured":"70) Flieswasser, T., Camara-Clayette, V., Danu, A., Bosq, J., Ribrag, V., Zabrocki, P., Van Rompaey, L., de Haard, H., Zwaenepoel, K., Smits, E., Pauwels, P. and Jacobs, J. (2019) Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method. Cancers (Basel) 11.","journal-title":"Cancers (Basel)"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"71) Kasap, C., Izgutdina, A., Patino-Escobar, B., Kang, A., Chilakapati, N., Akagi, N., Johnson, H., Rashid, T., Werner, J., Barpanda, A., Geng, H., Lin, Y.T., Rampersaud, S., Gil-Alos, D., Sobh, A., Dupere-Richer, D., Wicaksono, G., Kawehi Kelii, K.M., Dalal, R., Ramos, E., Vijayanarayanan, A., Salangsang, F., Phojanakong, P., Serrano, J.A.C., Zakraoui, O., Tariq, I., Steri, V., Shanmugam, M., Boise, L.H., Kortemme, T., Stieglitz, E., Licht, J.D., Karlon, W.J., Barwick, B.G. and Wiita, A.P. (2024) Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. bioRxiv.","DOI":"10.1101\/2024.02.24.581875"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","unstructured":"72) Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. and Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood 103, 2332-2336.","journal-title":"Blood"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","unstructured":"73) Ramos, C.A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R.T., Gee, A.P., Mei, Z., Wu, M.F., Liu, H., Grilley, B., Rooney, C.M., Brenner, M.K., Heslop, H.E. and Dotti, G. (2016) Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. J Clin Invest 126, 2588-2596.","journal-title":"J Clin Invest"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/icb.2013.17","article-title":"NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors","volume":"91","author":"Spear","year":"2013","unstructured":"74) Spear, P., Barber, A., Rynda-Apple, A. and Sentman, C.L. (2013) NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 91, 435-440.","journal-title":"Immunol Cell Biol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","unstructured":"75) Baumeister, S.H., Murad, J., Werner, L., Daley, H., Trebeden-Negre, H., Gicobi, J.K., Schmucker, A., Reder, J., Sentman, C.L., Gilham, D.E., Lehmann, F.F., Galinsky, I., DiPietro, H., Cummings, K., Munshi, N.C., Stone, R.M., Neuberg, D.S., Soiffer, R., Dranoff, G., Ritz, J. and Nikiforow, S. (2019) Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma. Cancer Immunol Res 7, 100-112.","journal-title":"Cancer Immunol Res"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"76) Li, C. and Mei, H. (2024) Anti-BCMA\/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2? Lancet Haematol 11, e712-e713.","DOI":"10.1016\/S2352-3026(24)00205-9"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-023-00436-9","article-title":"Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting","volume":"12","author":"Hou","year":"2023","unstructured":"77) Hou, J., Li, Y. and Lin, Q. (2023) Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. Exp Hematol Oncol 12, 74.","journal-title":"Exp Hematol Oncol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","author":"Zhou","year":"2024","unstructured":"78) Zhou, D., Sun, Q., Xia, J., Gu, W., Qian, J., Zhuang, W., Yan, Z., Cheng, H., Chen, W., Zhu, F., Qi, K., Li, D., Sang, W., Zhu, L., Ma, S., Li, H., Zhang, H., Qiu, T., Yan, D., Zhang, Y., Peng, S., Chang, A.H., Xu, K. and Li, Z. (2024) Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol 11, e751-e760.","journal-title":"Lancet Haematol 11 e751-e"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","unstructured":"79) Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., Yin, P., Wang, Z., Ai, L., Ke, S., Xia, Y., Deng, J., Chen, L., Cai, L., Sun, C., Xia, L., Hua, G. and Hu, Y. (2021) A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14, 161.","journal-title":"J Hematol Oncol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","unstructured":"80) Hsi, E.D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B.P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A.G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, J.D., Jr., Barlogie, B., van Rhee, F., Hussein, M., Afar, D.E. and Williams, M.B. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14, 2775-2784.","journal-title":"Clin Cancer Res"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","unstructured":"81) Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Rollig, C., Einsele, H., Wu, K.L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K.C., Richardson, P. and Investigators, E.-. (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373, 621-631.","journal-title":"N Engl J Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O'Neal","year":"2022","unstructured":"82) O'Neal, J., Ritchey, J.K., Cooper, M.L., Niswonger, J., Sofia Gonzalez, L., Street, E., Rettig, M.P., Gladney, S.W., Gehrs, L., Abboud, R., Prior, J.L., Haas, G.J., Jayasinghe, R.G., Ding, L., Ghobadi, A., Vij, R. and DiPersio, J.F. (2022) CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia 36, 1625-1634.","journal-title":"Leukemia"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","unstructured":"83) Li, C., Xu, J., Luo, W., Liao, D., Xie, W., Wei, Q., Zhang, Y., Wang, X., Wu, Z., Kang, Y., Zheng, J., Xiong, W., Deng, J., Hu, Y. and Mei, H. (2024) Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia 38, 149-159.","journal-title":"Leukemia"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma","author":"Sun","year":"2020","unstructured":"84) Sun, J., Muz, B., Alhallak, K., Markovic, M., Gurley, S., Wang, Z., Guenthner, N., Wasden, K., Fiala, M., King, J., Kohnen, D., Salama, N.N., Vij, R. and Azab, A.K. (2020) Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers (Basel) 12.","journal-title":"Cancers (Basel)"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12951-024-02512-6","article-title":"BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma","volume":"22","author":"Lu","year":"2024","unstructured":"85) Lu, Q., Li, H., Wu, Z., Zhu, Z., Zhang, Z., Yang, D. and Tong, A. (2024) BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. J Nanobiotechnology 22, 279.","journal-title":"J Nanobiotechnology"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cmet.2022.07.005","article-title":"CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder","author":"Wang","year":"2022","unstructured":"86) Wang, X., Liu, M., Zhang, J., Brown, N.K., Zhang, P., Zhang, Y., Liu, H., Du, X., Wu, W., Devenport, M., Tao, W., Mao-Draayer, Y., Chen, G.Y., Chen, Y.E., Zheng, P. and Liu, Y. (2022) CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. Cell Metab 34, 1088-1103 e1086.","journal-title":"Cell Metab 34 1088-1103 e"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","unstructured":"87) Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D., Xu, H., Gai, D., Siegel, E., Bailey, C., Ashby, C., Al Hadidi, S., Schinke, C., Thanendrarajan, S., Ma, Y., Yi, Q., Orlowski, R.Z., Zangari, M., van Rhee, F., Janz, S., Bishop, G., Tricot, G., Shaughnessy, J.D., Jr. and Zhan, F. (2024) Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat Commun 15, 615.","journal-title":"Nat Commun"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","unstructured":"88) Schmidts, A., Ormhoj, M., Choi, B.D., Taylor, A.O., Bouffard, A.A., Scarfo, I., Larson, R.C., Frigault, M.J., Gallagher, K., Castano, A.P., Riley, L.S., Cabral, M.L., Boroughs, A.C., Velasco Cardenas, R.M., Schamel, W., Zhou, J., Mackay, S., Tai, Y.T., Anderson, K.C. and Maus, M.V. (2019) Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 3, 3248-3260.","journal-title":"Blood Adv"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","unstructured":"89) Larson, R.C., Kann, M.C., Graham, C., Mount, C.W., Castano, A.P., Lee, W.H., Bouffard, A.A., Takei, H.N., Almazan, A.J., Scarfo, I., Berger, T.R., Schmidts, A., Frigault, M.J., Gallagher, K.M.E. and Maus, M.V. (2023) Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat Commun 14, 7509.","journal-title":"Nat Commun"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-23-0132","article-title":"Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138","volume":"29","author":"der Schans","year":"2023","unstructured":"90) van der Schans, J.J., Wang, Z., van Arkel, J., van Schaik, T., Katsarou, A., Ruiter, R., Baardemans, T., Yuan, H., de Bruijn, J., Zweegman, S., van de Donk, N., Groen, R.W.J., Themeli, M. and Mutis, T. (2023) Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138. Clin Cancer Res 29, 4219-4229.","journal-title":"Clin Cancer Res"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1172\/jci159527","article-title":"CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation","author":"Gai","year":"2022","unstructured":"91) Gai, D., Chen, J.R., Stewart, J.P., Nookaew, I., Habelhah, H., Ashby, C., Sun, F., Cheng, Y., Li, C., Xu, H., Peng, B., Garg, T.K., Schinke, C., Thanendrarajan, S., Zangari, M., Chen, F., Barlogie, B., van Rhee, F., Tricot, G., Shaughnessy, J.D., Jr. and Zhan, F. (2022) CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest 132.","journal-title":"J Clin Invest"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1172\/jci171396","article-title":"BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions","author":"Sun","year":"2024","unstructured":"92) Sun, F., Cheng, Y., Chen, J.R., Wanchai, V., Mery, D.E., Xu, H., Gai, D., Al Hadidi, S., Schinke, C., Thanendrarajan, S., Zangari, M., van Rhee, F., Tricot, G., Shaughnessy, J.D., Jr. and Zhan, F. (2024) BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest 134.","journal-title":"J Clin Invest"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"40","author":"Wang","year":"2022","unstructured":"93) Wang, Y., Cao, J., Gu, W., Shi, M., Lan, J., Yan, Z., Jin, L., Xia, J., Ma, S., Liu, Y., Li, H., Pan, B., Chen, W., Fei, X., Wang, C., Xie, X., Yu, L., Wang, G., Li, H., Jing, G., Cheng, H., Zhu, F., Sun, H., Sang, W., Li, D., Li, Z., Zheng, J. and Xu, K. (2022) Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol 40, 2246-2256.","journal-title":"J Clin Oncol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","unstructured":"94) Fu, W., Lei, C., Liu, S., Cui, Y., Wang, C., Qian, K., Li, T., Shen, Y., Fan, X., Lin, F., Ding, M., Pan, M., Ye, X., Yang, Y. and Hu, S. (2019) CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun 10, 4355.","journal-title":"Nat Commun"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"103354","DOI":"10.1016\/j.ebiom.2021.103354","article-title":"Delivery technologies for T cell gene editing: Applications in cancer immunotherapy","volume":"67","author":"Atsavapranee","year":"2021","unstructured":"95) Atsavapranee, E.S., Billingsley, M.M. and Mitchell, M.J. (2021) Delivery technologies for T cell gene editing: Applications in cancer immunotherapy. EBioMedicine 67, 103354.","journal-title":"EBioMedicine"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2022-005189","article-title":"Automated, scaled, transposon-based production of CAR T cells","author":"Lock","year":"2022","unstructured":"96) Lock, D., Monjezi, R., Brandes, C., Bates, S., Lennartz, S., Teppert, K., Gehrke, L., Karasakalidou-Seidt, R., Lukic, T., Schmeer, M., Schleef, M., Werchau, N., Eyrich, M., Assenmacher, M., Kaiser, A., Prommersberger, S., Schaser, T. and Hudecek, M. (2022) Automated, scaled, transposon-based production of CAR T cells. J Immunother Cancer 10.","journal-title":"J Immunother Cancer"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma","volume":"28","author":"Meister","year":"2022","unstructured":"97) Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B.D., Snijder, B., Regli, L., Ravi, V.M., Heiland, D.H., Sentman, C.L., Weller, M. and Weiss, T. (2022) Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. Clin Cancer Res 28, 4747-4756.","journal-title":"Clin Cancer Res"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","unstructured":"98) Kitte, R., Rabel, M., Geczy, R., Park, S., Fricke, S., Koehl, U. and Tretbar, U.S. (2023) Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Mol Ther Methods Clin Dev 31, 101139.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","article-title":"Polymer- and lipid-based gene delivery technology for CAR T cell therapy","volume":"353","author":"Pinto","year":"2023","unstructured":"99) Pinto, I.S., Cordeiro, R.A. and Faneca, H. (2023) Polymer- and lipid-based gene delivery technology for CAR T cell therapy. J Control Release 353, 196-215.","journal-title":"J Control Release"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","unstructured":"100) Mansoori, S., Noei, A., Maali, A., Seyed-Motahari, S.S. and Sharifzadeh, Z. (2024) Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell Int 24, 304.","journal-title":"Cancer Cell Int"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","unstructured":"101) Mailankody, S., Matous, J.V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O.O., Malik, S., Nath, R., Anwer, F., Cruz, J.C., Htut, M., Karski, E.E., Lovelace, W., Dillon, M., Butz, E., Ying, W., Balakumaran, A. and Kumar, S.K. (2023) Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 29, 422-429.","journal-title":"Nat Med"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","unstructured":"102) Dagher, O.K. and Posey, A.D., Jr. (2023) Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol 24, 1994-2007.","journal-title":"Nat Immunol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40164-023-00461-8","article-title":"Single VHH-directed BCMA CAR-NK cells for multiple myeloma","volume":"12","author":"Ren","year":"2023","unstructured":"103) Ren, Q., Zu, Y., Su, H., Lu, Q., Xiang, B., Luo, Y., Zhang, J. and Song, Y. (2023) Single VHH-directed BCMA CAR-NK cells for multiple myeloma. Exp Hematol Oncol 12, 98.","journal-title":"Exp Hematol Oncol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","unstructured":"104) Zhang, X., Zhang, H., Lan, H., Wu, J. and Xiao, Y. (2023) CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol 14, 1101495.","journal-title":"Front Immunol"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"105) Costa, L.J., Kumar, S., Atrash, S., Liedtke, M., Kaur, G., Derman, B.A., Bergsagel, P.L., Mailankody, S., McCarthy, P.L., Limones, J., Chen, Y., Das, S., Thorpe, J., Cacciatore, J., Navarro, G., Koegel, A.K., Burgess, M.R., Hege, K. and Richard, S. (2022) Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM), The American Society of Hematology Annual Meeting, New Orleans, LA, USA.","DOI":"10.1182\/blood-2022-160038"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","unstructured":"106) Rejeski, K., Hansen, D.K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J.M., Braunlein, E., Cordas Dos Santos, D.M., Freeman, C.L., Alsina, M., Theurich, S., Wang, Y., Krackhardt, A.M., Locke, F.L., Bachy, E., Jain, M.D., Lin, Y. and Subklewe, M. (2023) The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol 16, 88.","journal-title":"J Hematol Oncol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Gagelmann","year":"2024","unstructured":"107) Gagelmann, N., Dima, D., Merz, M., Hashmi, H., Ahmed, N., Tovar, N., Oliver-Caldes, A., Stolzel, F., Rathje, K., Fischer, L., Born, P., Schafer, L., Albici, A.M., Schub, N., Kfir-Erenfeld, S., Assayag, M., Asherie, N., Wulf, G.G., Kharboutli, S., Muller, F., Shune, L., Davis, J.A., Anwer, F., Vucinic, V., Platzbecker, U., Ayuk, F., Kroger, N., Khouri, J., Gurnari, C., McGuirk, J., Stepensky, P., Abdallah, A.O. and Fernandez de Larrea, C. (2024) Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma. J Clin Oncol 42, 1665-1675.","journal-title":"J Clin Oncol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Saldarriaga","year":"2024","unstructured":"108) Mejia Saldarriaga, M., Pan, D., Unkenholz, C., Mouhieddine, T.H., Velez-Hernandez, J.E., Engles, K., Fein, J.A., Monge, J., Rosenbaum, C., Pearse, R., Jayabalan, D., Gordillo, C., Chan, H.T., Yamshon, S., Thibaud, S., Mapara, M., Inghirami, G., Lentzsch, S., Reshef, R., Rossi, A., Parekh, S., Jagannath, S., Richard, S., Niesvizky, R. and Bustoros, M. (2024) Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv 8, 3859-3869.","journal-title":"Blood Adv"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1169071","DOI":"10.3389\/fimmu.2023.1169071","article-title":"A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells","volume":"14","author":"Liu","year":"2023","unstructured":"109) Liu, Y., Jie, X., Nian, L., Wang, Y., Wang, C., Ma, J., Jiang, J., Wu, Q., Qiao, J., Chen, W., Cao, J., Yan, Z., Shi, M., Cheng, H., Zhu, F., Sang, W., Li, D., Chen, C., Xu, K. and Li, Z. (2023) A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol 14, 1169071.","journal-title":"Front Immunol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjh.18873","article-title":"Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study","volume":"202","author":"Zhou","year":"2023","unstructured":"110) Zhou, L., Fu, W., Wu, S., Xu, K., Qiu, L., Xu, Y., Yan, X., Zhang, Q., Zhang, M., Wang, L., Hong, R., Chang, A.H., Yu, J., Fu, S., Kong, D., Li, L., Wang, Y., Li, Z., Jiang, H., Huang, J., Liu, Z., Su, N., Wei, G., Hu, Y. and Huang, H. (2023) Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol 202, 517-524.","journal-title":"Br J Haematol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"101082","DOI":"10.1016\/j.drup.2024.101082","article-title":"Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies","volume":"74","author":"Huang","year":"2024","unstructured":"111) Huang, Y., Qin, Y., He, Y., Qiu, D., Zheng, Y., Wei, J., Zhang, L., Yang, D.H. and Li, Y. (2024) Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updat 74, 101082.","journal-title":"Drug Resist Updat"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","unstructured":"112) Zhao, G., Wei, R., Feng, L., Wu, Y., He, F., Xiao, M. and Cheng, Z. (2022) Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature. Cancer Immunol Immunother 71, 39-44.","journal-title":"Cancer Immunol Immunother"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"111594","DOI":"10.1080\/2162402x.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","author":"Otahal","year":"2016","unstructured":"113) Otahal, P., Prukova, D., Kral, V., Fabry, M., Vockova, P., Lateckova, L., Trneny, M. and Klener, P. (2016) Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 5, e1115940.","journal-title":"Oncoimmunology 5 e"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2022.281339","article-title":"All-trans retinoic acid works synergistically with the gamma-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells","volume":"108","author":"Garcia-Guerrero","year":"2023","unstructured":"114) Garcia-Guerrero, E., Rodriguez-Lobato, L.G., Sierro-Martinez, B., Danhof, S., Bates, S., Frenz, S., Haertle, L., Gotz, R., Sauer, M., Rasche, L., Kortum, K.M., Perez-Simon, J.A., Einsele, H., Hudecek, M. and Prommersberger, S.R. (2023) All-trans retinoic acid works synergistically with the gamma-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica 108, 568-580.","journal-title":"Haematologica"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"108382","DOI":"10.1016\/j.clim.2020.108382","article-title":"Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies","volume":"214","author":"Song","year":"2020","unstructured":"115) Song, W. and Zhang, M. (2020) Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clin Immunol 214, 108382.","journal-title":"Clin Immunol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments","volume":"8","author":"Xie","year":"2020","unstructured":"116) Xie, Y.J., Dougan, M., Ingram, J.R., Pishesha, N., Fang, T., Momin, N. and Ploegh, H.L. (2020) Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. Cancer Immunol Res 8, 518-529.","journal-title":"Cancer Immunol Res"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2217\/imt-2020-0116","article-title":"Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function","volume":"12","author":"Wei","year":"2020","unstructured":"117) Wei, S., Gu, R., Xu, Y., Liu, X., Xing, Y., Gong, X., Zhou, C., Liu, B., Zhang, G., Liu, K., Wei, H., Mi, Y., Wang, M., Wang, Y. and Wang, J. (2020) Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function. Immunotherapy 12, 1047-1052.","journal-title":"Immunotherapy"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy","volume":"26","author":"Huarte","year":"2020","unstructured":"118) Huarte, E., O'Connor, R.S., Peel, M.T., Nunez-Cruz, S., Leferovich, J., Juvekar, A., Yang, Y.O., Truong, L., Huang, T., Naim, A., Milone, M.C. and Smith, P.A. (2020) Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clin Cancer Res 26, 6299-6309.","journal-title":"Clin Cancer Res"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"119) Kale, S.D., Mehrkens, B.N., Stegman, M.M., Kastelberg, B., Carnes, H., McNeill, R.J., Rizzo, A., Karyala, S.V., Coutermarsh-Ott, S., Fretz, J.A., Sun, Y., Koff, J.L. and Rajagopalan, G. (2020) \"Small\" Intestinal Immunopathology Plays a \"Big\" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-gamma, IL-17A, and a Janus Kinase Inhibitor. Front Immunol 11, 1311.","DOI":"10.3389\/fimmu.2020.01311"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood.2019001645","article-title":"Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy","volume":"135","author":"Vinanica","year":"2020","unstructured":"120) Vinanica, N., Yong, A., Wong, D., Png, Y.T., Seow, S.V., Imamura, M. and Campana, D. (2020) Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. Blood 135, 668-679.","journal-title":"Blood"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12967-023-04655-w","article-title":"A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma","volume":"21","author":"Wang","year":"2023","unstructured":"121) Wang, D., Fu, H., Que, Y., Ruan, H., Xu, M., Long, X., Yu, Q., Li, C., Li, Z., Cai, S., Chen, W., Sun, C., Hu, G., Wang, S., He, D., Mei, J., Wang, W. and Li, C. (2023) A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma. J Transl Med 21, 812.","journal-title":"J Transl Med"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"20406207241237594","DOI":"10.1177\/20406207241237594","article-title":"Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma","volume":"15","author":"Yuan","year":"2024","unstructured":"122) Yuan, S., Chen, Y. and Liu, H. (2024) Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma. Ther Adv Hematol 15, 20406207241237594.","journal-title":"Ther Adv Hematol"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","unstructured":"123) Shi, X., Yan, L., Shang, J., Kang, L., Yan, Z., Jin, S., Zhu, M., Chang, H., Gong, F., Zhou, J., Chen, G., Pan, J., Liu, D., Zhu, X., Tang, F., Liu, M., Liu, W., Yao, F., Yu, L., Wu, D. and Fu, C. (2022) Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol 97, 537-547.","journal-title":"Am J Hematol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s00262-023-03461-z","article-title":"Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma","volume":"72","author":"Awuah","year":"2023","unstructured":"124) Awuah, D., Minnix, M., Caserta, E., Tandoh, T., Adhikarla, V., Poku, E., Rockne, R., Pichiorri, F., Shively, J.E. and Wang, X. (2023) Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma. Cancer Immunol Immunother 72, 2841-2849.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T10:53:12Z","timestamp":1736938392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oftalmoloji.org\/articles\/an-unusual-case-of-low-vision-and-anisocoria-considered-a-neurological-finding-in-the-emergency-department-ocular-siderosis\/doi\/tjo.galenos.2024.77783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":124,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2024.77783","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}